(DOC) Healthpeak Properties - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US42250P1030
Stock:
Total Rating 29
Risk 41
Buy Signal -0.45
| Risk 5d forecast | |
|---|---|
| Volatility | 26.3% |
| Relative Tail Risk | -2.62% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -17.56 |
| Character TTM | |
|---|---|
| Beta | 0.559 |
| Beta Downside | 1.070 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.80% |
| CAGR/Max DD | -0.10 |
EPS (Earnings per Share)
Revenue
Primary Risks
P/E ratio: 170.6
Description: DOC Healthpeak Properties
Healthpeak Properties, Inc. is a Standard & Poor's 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States. Our company was originally founded in 1985. We are organized as an umbrella partnership REIT. We hold substantially all our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S. We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and continuing care retirement community real estate. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Under the CCRC segment, our properties are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our 'SWF SH JV'), (ii) loans receivable, and (iii) a preferred equity investment. These non-reportable segments have been presented on a combined basis herein. At September 30, 2025, our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in 703 properties: (i) Outpatient medical ' 530 properties; (ii) Lab ' 139 properties; (iii) CCRC ' 15 properties; and (iv) Other non-reportable ' 19 properties.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 71.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 3.12% < 20% (prev 4.10%; Δ -0.98% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.26b > Net Income 71.3m |
| Net Debt (9.90b) to EBITDA (1.60b): 6.18 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (696.0m) vs 12m ago -0.51% < -2% |
| Gross Margin: 22.48% > 18% (prev 0.60%; Δ 2188 % > 0.5%) |
| Asset Turnover: 14.02% > 50% (prev 13.54%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 1.78 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 305.2m) |
Altman Z'' -1.20
| A: 0.00 (Total Current Assets 1.07b - Total Current Liabilities 985.3m) / Total Assets 20.34b |
| B: -0.29 (Retained Earnings -5.95b / Total Assets 20.34b) |
| C: 0.03 (EBIT TTM 544.1m / Avg Total Assets 20.14b) |
| D: -0.44 (Book Value of Equity -5.27b / Total Liabilities 12.03b) |
| Altman-Z'' Score: -1.20 = CCC |
Beneish M -1.68
| DSRI: 0.82 (Receivables 684.3m/794.0m, Revenue 2.82b/2.70b) |
| GMI: 2.68 (GM 22.48% / 60.20%) |
| AQI: 1.00 (AQ_t 0.93 / AQ_t-1 0.93) |
| SGI: 1.05 (Revenue 2.82b / 2.70b) |
| TATA: -0.06 (NI 71.3m - CFO 1.26b) / TA 20.34b) |
| Beneish M-Score: -1.68 (Cap -4..+1) = CCC |
What is the price of DOC shares?
As of February 25, 2026, the stock is trading at USD 17.25 with a total of 5,268,746 shares traded.
Over the past week, the price has changed by +0.17%, over one month by -2.26%, over three months by -1.57% and over the past year by -7.27%.
Over the past week, the price has changed by +0.17%, over one month by -2.26%, over three months by -1.57% and over the past year by -7.27%.
Is DOC a buy, sell or hold?
Healthpeak Properties has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy DOC.
- StrongBuy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.9 | 15.2% |
| Analysts Target Price | 19.9 | 15.2% |
DOC Fundamental Data Overview February 21, 2026
P/E Trailing = 170.6
P/E Forward = 111.1111
P/S = 4.201
P/B = 1.5476
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 8.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortLongTermDebt, last quarter)
Debt = 10.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.90b USD (from netDebt column, last quarter)
Enterprise Value = 21.83b USD (11.86b + Debt 10.44b - CCE 467.5m)
Interest Coverage Ratio = 1.78 (Ebit TTM 544.1m / Interest Expense TTM 305.2m)
EV/FCF = 18.19x (Enterprise Value 21.83b / FCF TTM 1.20b)
FCF Yield = 5.50% (FCF TTM 1.20b / Enterprise Value 21.83b)
FCF Margin = 42.51% (FCF TTM 1.20b / Revenue TTM 2.82b)
Net Margin = 2.53% (Net Income TTM 71.3m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = -87.20% (prev 58.64%)
Tobins Q-Ratio = 1.07 (Enterprise Value 21.83b / Total Assets 20.34b)
Interest Expense / Debt = 0.77% (Interest Expense 80.6m / Debt 10.44b)
Taxrate = 4.72% (6.03m / 127.8m)
NOPAT = 518.5m (EBIT 544.1m * (1 - 4.72%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.39 (Debt 10.44b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 6.18 (Net Debt 9.90b / EBITDA 1.60b)
Debt / FCF = 8.25 (Net Debt 9.90b / FCF TTM 1.20b)
Total Stockholder Equity = 7.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 71.3m / Total Assets 20.34b)
RoE = 0.91% (Net Income TTM 71.3m / Total Stockholder Equity 7.80b)
RoCE = 3.28% (EBIT 544.1m / Capital Employed (Equity 7.80b + L.T.Debt 8.77b))
RoIC = 3.04% (NOPAT 518.5m / Invested Capital 17.03b)
WACC = 4.59% (E(11.86b)/V(22.30b) * Re(7.98%) + D(10.44b)/V(22.30b) * Rd(0.77%) * (1-Tc(0.05)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.77%
[DCF] Terminal Value 87.32% ; FCFF base≈1.15b ; Y1≈1.28b ; Y5≈1.67b
[DCF] Fair Price = 56.46 (EV 49.14b - Net Debt 9.90b = Equity 39.24b / Shares 695.0m; r=5.90% [WACC]; 5y FCF grow 12.79% → 2.90% )
EPS Correlation: -33.73 | EPS CAGR: 13.23% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 10.28% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=-0.027 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=0.19 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+387.2% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=-0.055 | Revisions Net=-1 | Growth EPS=+5.3% | Growth Revenue=+3.7%
[Gordon] Analyst Rev G=-0.1% | Discount Rate=8.0% | Earnings Yield=0.6% | Net Margin=2.5% | ROE=0.9% | Plowback=-10.9% | Payout=110.9%
[Gordon] Breakeven Revenue = 34.20b USD (current 2.82b)
[Gordon] Implied Growth Rate = 7.4% (Discount Rate 8.0% - Earnings Yield 0.6%)
[Gordon] Growth Spread = -7.5% (Analyst -0.1% - Implied 7.4%)
P/E Forward = 111.1111
P/S = 4.201
P/B = 1.5476
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 8.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortLongTermDebt, last quarter)
Debt = 10.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.90b USD (from netDebt column, last quarter)
Enterprise Value = 21.83b USD (11.86b + Debt 10.44b - CCE 467.5m)
Interest Coverage Ratio = 1.78 (Ebit TTM 544.1m / Interest Expense TTM 305.2m)
EV/FCF = 18.19x (Enterprise Value 21.83b / FCF TTM 1.20b)
FCF Yield = 5.50% (FCF TTM 1.20b / Enterprise Value 21.83b)
FCF Margin = 42.51% (FCF TTM 1.20b / Revenue TTM 2.82b)
Net Margin = 2.53% (Net Income TTM 71.3m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = -87.20% (prev 58.64%)
Tobins Q-Ratio = 1.07 (Enterprise Value 21.83b / Total Assets 20.34b)
Interest Expense / Debt = 0.77% (Interest Expense 80.6m / Debt 10.44b)
Taxrate = 4.72% (6.03m / 127.8m)
NOPAT = 518.5m (EBIT 544.1m * (1 - 4.72%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.39 (Debt 10.44b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 6.18 (Net Debt 9.90b / EBITDA 1.60b)
Debt / FCF = 8.25 (Net Debt 9.90b / FCF TTM 1.20b)
Total Stockholder Equity = 7.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 71.3m / Total Assets 20.34b)
RoE = 0.91% (Net Income TTM 71.3m / Total Stockholder Equity 7.80b)
RoCE = 3.28% (EBIT 544.1m / Capital Employed (Equity 7.80b + L.T.Debt 8.77b))
RoIC = 3.04% (NOPAT 518.5m / Invested Capital 17.03b)
WACC = 4.59% (E(11.86b)/V(22.30b) * Re(7.98%) + D(10.44b)/V(22.30b) * Rd(0.77%) * (1-Tc(0.05)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.77%
[DCF] Terminal Value 87.32% ; FCFF base≈1.15b ; Y1≈1.28b ; Y5≈1.67b
[DCF] Fair Price = 56.46 (EV 49.14b - Net Debt 9.90b = Equity 39.24b / Shares 695.0m; r=5.90% [WACC]; 5y FCF grow 12.79% → 2.90% )
EPS Correlation: -33.73 | EPS CAGR: 13.23% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 10.28% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=-0.027 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=0.19 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+387.2% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=-0.055 | Revisions Net=-1 | Growth EPS=+5.3% | Growth Revenue=+3.7%
[Gordon] Analyst Rev G=-0.1% | Discount Rate=8.0% | Earnings Yield=0.6% | Net Margin=2.5% | ROE=0.9% | Plowback=-10.9% | Payout=110.9%
[Gordon] Breakeven Revenue = 34.20b USD (current 2.82b)
[Gordon] Implied Growth Rate = 7.4% (Discount Rate 8.0% - Earnings Yield 0.6%)
[Gordon] Growth Spread = -7.5% (Analyst -0.1% - Implied 7.4%)